肿瘤时间肺癌精准治疗的新靶标——MET 14 号外显子跳跃突变的检测( 三 )


精准定位才能精准打击 , 相信随着检测技术的发展 , 具有 MET 14 号外显子跳跃突变的患者将不再与靶向治疗「擦肩而过」 。
参考文献
1. Paik PK, et al. Response to MET inhibitors in patients with stage IV lung adenocarcinomas harboring MET mutations causing exon 14 skipping. Cancer Discov. 2015;5(8):842-849.
2.Awad MM. Impaired c-Met Receptor Degradation Mediated by MET Exon 14 Mutations in Non-Small-Cell Lung Cancer. J Clin Oncol. 2016;34(8): 879-881.
4. Poirot B, et al. MET Exon 14 Alterations and New Resistance Mutations to Tyrosine Kinase Inhibitors: Risk of Inadequate Detection with Current Amplicon-Based NGS Panels. J Thorac Oncol. 2017;12(10):1582-1587.
5. 中国临床肿瘤学会指南工作委员会. 中国临床肿瘤学会(CSCO)原发性肺癌诊疗指南-2019-Primary lung cancer. 人民卫生出版社. 2019.
CN-60076
题图来源丨站酷海洛


推荐阅读